Drug discovery and development affects various aspects of human health and dramatically
impacts the pharmaceutical market. However, investments in a new drug often go …

The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …

Summary KRAS G12C was recently identified to be potentially druggable by allele-specific
covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP) …

De novo and acquired resistance, which are largely attributed to genetic alterations, are
barriers to effective anti-epidermal-growth-factor-receptor (EGFR) therapy. To generate …

The systematic translation of cancer genomic data into knowledge of tumour biology and
therapeutic possibilities remains challenging. Such efforts should be greatly aided by robust …

Clinical responses to anticancer therapies are often restricted to a subset of patients. In
some cases, mutated cancer genes are potent biomarkers for responses to targeted agents …

The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was
designed to classify patients with metastatic gastric cancer based on clinical sequencing …

Aberrant activation of the RAS–RAF–MEK–ERK1/2 pathway occurs in more than 30% of
human cancers. As part of this pathway, MEK1 and MEK2 have crucial roles in …

Dual‐specificity MAP kinase phosphatases (MKPs) provide a complex negative regulatory
network that acts to shape the duration, magnitude and spatiotemporal profile of MAP kinase …

Treatment decisions for patients with lung cancer have historically been based on tumour
histology. Some understanding of the molecular composition of tumours has led to the …